Haleos Labs Limited

NSE: HALEOSLABS · Pharmaceuticals · sector

₹1,463.70NSE close 2026-10-26

Key numbers

Market cap₹443 cr

Price₹1,463.70

52w high / low₹1,774 / ₹1,091

P/E28.0xSector median 27.9x

P/B2.1xSector median 2.9x

Book value₹706.3

Dividend yield0.10%Sector median 0.48%

ROE7.7%Sector median 11.7%

ROCE8.7%Sector median 12.3%

OPM12.6%Sector median 14.0%

Debt / equity0.51xSector median 0.16x

EV/EBITDA13.4xSector median 18.6x

Interest cover4.3x

Current ratio1.04x

Sales growth 3y+1.9%Sector median +9.6%

Profit growth 3y+14.7%Sector median +13.3%

PEG1.90x

Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹2 cr vs borrowings ₹109 cr (FY26): borrowings are higher by ₹106 cr.
Operating profit covered interest 4.3x in the last 12 months.
No promoter shares are pledged.
Promoter holding rose by 0.70 percentage points in a year, to 72.11% (2026-09-30).
Operating cash flow was below net profit in 1 of the last 5 years (FY22).
Revenue was higher than a year earlier in 2 of the last 4 quarters.
Other income was 20% of net profit in the last 12 months.
Dividend paid in 5 of the last 5 financial years.
Price ₹1,463.70 on 2026-10-26: -17.5% from the 52-week high, +34.1% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹1,664.00 · low ₹1,044.35

Quarterly results

₹ cr	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	78	85	89	82	81	95	75	73
EBITDA	9	13	7	12	14	14	4	9
OPM %	10.9%	15.1%	8.3%	14.2%	16.7%	14.8%	5.5%	12.5%
Other income	2	0	2	1	0	0	2	0
Net profit	5	5	3	4	6	7	0	3
EPS (₹)	15.46	18.08	9.83	13.75	20.19	21.89	1.44	8.75
Revenue YoY					+3.7%	+12.0%	-15.7%	-11.6%
Profit YoY					+30.6%	+21.0%	-85.2%	-36.3%

Consolidated figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY22	FY23	FY24	FY25	FY26	TTM
Revenue	350	316	306	345	334	324
EBITDA	47	31	31	45	45	41
Net profit	25	11	9	20	17	16
EPS (₹)	83.68	37.92	30.08	66.51	57.26	52.27
Revenue growth		-9.8%	-3.0%	+12.7%	-3.2%	-3.1%
Profit growth		-54.7%	-20.7%	+121.2%	-13.9%	-8.5%
Dividend / share (₹)	1.50	1.50	1.50	1.50	1.50

Compounded growth	3 years	5 years	Last 12 months
Sales	+1.9%	+4.7%	-3.1%
Net profit	+14.7%	+5.0%	-8.5%
EPS	+14.7%	+5.0%	–
Share price	–	– (2y)	–

Balance sheet

₹ cr	FY22	FY23	FY24	FY25	FY26
Shareholders' equity	–	169	177	197	214
Borrowings	–	99	98	84	109
Cash & equivalents	–	4	1	2	2
Total assets	–	395	391	390	454
Fixed assets	–	227	221	230	267
Capital work in progress	–	1	6	0	10
Investments	–	0	0	0	0
Receivables	–	46	51	69	61
Inventory	–	86	81	67	80
Payables	–	60	59	53	61

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY22	FY23	FY24	FY25	FY26
Cash from operations	-11	15	24	34	37
Cash from investing	-7	-31	-18	-15	-58
Cash from financing	11	17	-7	-19	21
Capex	51	49	21	15	58
Free cash flow	-62	-34	3	19	-21

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY22	FY23	FY24	FY25	FY26
ROE %	–	6.8%	5.1%	10.2%	8.1%
ROCE %	–	8.8%	7.3%	12.4%	9.8%
Debtor days	–	53	61	73	67
Inventory days	–	184	196	160	210
Payable days	–	127	143	126	162
Cash conversion cycle (days)	–	110	114	107	115
Working capital days	–	30	13	9	7

Shareholding

Holder	% (2026-09-30)
Promoters	72.11%
DIIs	0.31%
Public (non-institutions)	27.58%

Quarter	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters %	71.41%	71.41%	71.41%	71.41%	71.80%	72.11%	72.11%	72.11%

Promoter group	%
Annapurna Talluri	24.56%
TVVSN Murthy	15.88%
Venkata Praveen Talluri	9.06%
Ramesh Babu Potluri	7.94%
Sudeepthi Gopineedi	6.60%
Hima Bindu Potluri	2.76%
Trilok Potluri	2.58%
Vamsi Krishna Potluri	2.42%
Potluri Infra Projects LLP	0.26%
Sukumari Koneru	0.02%
Venkata Chaitanya Gopineedi	0.01%
TVVSN MURTHY (HUF) (Karta - Mr.TVVSN Murthy)	0.00%
Rajeswara RAO Gopineedi	0.00%
Potluri Laboratories Private Limited	0.00%
Pixalot Labs Private Limited	0.00%

Public holders above 1%	%
Harita Projects Private	1.76%
Vijayakumar S	1.11%

6,765 shareholders. Pledged: 0.00% of promoter shares.

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
HALEOSLABS	₹443 cr	28.0x	2.1x	7.7%	8.7%	12.6%	+1.9%	0.10%

All 185 companies in Pharmaceuticals →

Dividends & corporate actions

Ex-date	Action	Detail
2026-09-23	Dividend	Dividend - Rs 1.50 Per Share
2025-09-24	Dividend	Dividend - Rs 1.50 Per Share
2024-09-23	Dividend	Annual General Meeting/Dividend - Rs 1.50 Per Share
2023-09-22	Dividend	Annual General Meeting/Dividend - Rs 1.50 Per Share
2022-09-22	Dividend	Annual General Meeting/Dividend - Rs 1.50 Per Share
2021-09-20	Dividend	Annual General Meeting/Dividend - Rs 1.50 Per Share
2019-09-19	Dividend	Dividend - Rs 1.50 Per Share
2018-09-12	Other	Annual General Meeting

Documents

Links go to the original files on the exchange website.

About the company


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	HALEOSLABS
BSE code	540679
ISIN	INE320X01016
Face value	₹10.0
Incorporated	–
Website	–
Plants (India / abroad)	–

Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.